Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
Date:10/7/2008

- Planned 15 Patient Cohort Enrolled in Stage A of Trial Assessing Regimen

of Bavituximab in Combination With Carboplatin and Paclitaxel -

TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. This is Peregrine's second Phase II study for the treatment of breast cancer. The main objective of the multi-center, open-label safety and efficacy study is to assess patients' overall response rate to a regimen combining bavituximab with the chemotherapy drugs carboplatin and paclitaxel. Patients in the study are receiving the treatment regimen and are being evaluated regularly for tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Peregrine president and CEO, Steven W. King noted, "We are very pleased that the sites were able to rapidly complete enrollment in the first part of this important Phase ll study. We look forward to generating clinical data from both of our ongoing Phase ll studies in advanced breast cancer patients over the coming months that will enable us to better assess bavituximab's early potential as a novel targeted therapy for breast cancer."

As part of this trial's Simon two-stage design, 15 patients with advanced breast cancer have been enrolled in Stage A of the study. The trial may be expanded to include up to an additional 31 subjects if promising results are seen in the Stage A cohort. The primary ob
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
4. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
5. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
7. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
10. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the second quarter ended June 30, 2014, a ... the same period of 2013. During the ... were sold globally compared to 523 units in the ...
(Date:7/31/2014)... 2014 Second Quarter Total Revenue $2.0 billion; an increase of ... 4% for same store sales and 8% pro forma, excluding ... , 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, ... Operating Cash Flow $376 million; Adjusted Operating Cash Flow $500 ... Launched 17 new products in the U.S. year-to-date , ...
(Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
Breaking Medicine Technology:HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25
... PARSIPPANY, N.J., Sept. 15, 2011 Fidia Farmaceutici S.p.A. ... ® (sodium hyaluronate), an injectable treatment for knee ... and physical therapy are not enough, will be transferred ... 24, 2011.  Fidia Farmaceutici S.p.A. is the owner and ...
... September 15, 2011 Oramed Pharmaceuticals Inc. ... oral delivery systems, announced today that Ehud Arbit, M.D., ... present at the 8th Annual Israel Strategic Partner and ... Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ on ...
Cached Medicine Technology:HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A. 2Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011 2
(Date:7/31/2014)... Thousands of independent community pharmacists, ... have come together today to kick off ThoughtSpot ... , "ThoughtSpot 2014 is Good Neighbor Pharmacy’s annual ... to help their businesses thrive," stated AJ Caffentzis, ... long-standing commitment to independent community pharmacies, and at ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... Agebc.com, a popular online shop of wedding dresses and women’s ... mother of the bride dresses . Aside from that, ... to 68% off. , “We are proud to enrich ... of the bride dresses. We launch the special offer to ... shop has received thousands of rave reviews from new and ...
(Date:7/31/2014)... new study by researchers at Sanford-Burnham Medical Research Institute ... convert existing cells in the pancreas into those cells ... published online July 31 in Cell Death and ... estimated 3 million people in the U.S., and over ... "We have found a promising technique for type 1 ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Quincy Bioscience, ... of brain health supplement Prevagen®, releases the second edition ... Marvelous Tips for Making Memories: Birth of a Grandchild. ... that offers exceptional memory-making tips and ideas for grandparents ... birth of a grandchild. Each concept published in the ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 2Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Mother of the Bride Dresses Now Available With Great Discounts at Agebc.com 2Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2Health News:Quincy Bioscience Launches the Second E-Book of the Making Memories Series 2
... Surprising finding shows it reduces risk of death, recurrence , ... soy foods can help lower the risk of death and ... shows. , What,s more, the association between soy and a ... estrogen receptor-positive cancers and women taking tamoxifen, according to the ...
... ... that a new market research report is available ... for Interventional Cardiology 2009 (15 Countries) ... European market for interventional cardiology was valued at ...
... , ... new market research report is available in its catalogue: ... Players, and Important Trends) , http://www.reportlinker.com/p0167109/EMR-2010-Market-Analysis-ARRA-Incentives-Key-Players-and-Important-Trends.html ... Kalorama Information surveyed the market for electronic medical records. ...
... your cool with misbehaving children is a challenge. We all ... out at someone without thinking. A new study by ... parents with poorer working memory skills are less likely to ... "Angry, oppositional behavior in children is aversive and challenging to ...
... , Woodbury, N.Y., Dec. 8 On December 9 ... and Miami schools to perform the live nutrition rock concert, ... Dietitian and musician is appearing free to schools courtesy of ... programs. This interactive show promotes healthy eating by ...
... Dec. 8 Tipping Point Community, a charitable organization dedicated ... million donation from the Sergey Brin and Anne Wojcicki Foundation. ... Annual Awards Breakfast and is one of Tipping Point,s largest ... one-quarter of families are too poor to meet their basic ...
Cached Medicine News:Health News:Soy Beneficial for Breast Cancer Survivors: Study 2Health News:Soy Beneficial for Breast Cancer Survivors: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 2Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 3Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 4Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 5Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 6Health News:Breakfast BREAKS(R) 'Jump with Jill' Rockin' Nutrition Show Kicks off Tour in Florida Schools 2Health News:Tipping Point Community Announces $1 Million Gift at Third Annual Awards Breakfast 2
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 600....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 700....
Designed to remove cell debris or tissue remnants from the retina....
... Medtronic presents the Streamline family of ... have taken the gold standard in temporary ... that make them easy to use and ... Streamline Temporary Pacing Leads are designed to ...
Medicine Products: